Terms: = Lung cancer AND FGFR4, CD334, 2264, ENSG00000160867, P22455, MGC20292, TKF, JTK2 AND Prognosis
16 results:
1. Prognostic Analysis of Different Metastatic Patterns in Invasive Intraductal Papillary Mucinous Neoplasm: A Surveillance, Epidemiology, and End Results Database Analysis.
Zhou C; Liu Z; Zhou Y; Ren D; Liu K; Qin G; Zhang H; Liang X; Gou S; Wu H
Can J Gastroenterol Hepatol; 2021; 2021():4350417. PubMed ID: 35047460
[TBL] [Abstract] [Full Text] [Related]
2. Development of a prognostic signature of patients with esophagus adenocarcinoma by using immune-related genes.
Zhang X; Yang L; Kong M; Ma J; Wei Y
BMC Bioinformatics; 2021 Nov; 22(1):536. PubMed ID: 34724890
[TBL] [Abstract] [Full Text] [Related]
3. Genomic comparison between cerebrospinal fluid and primary tumor revealed the genetic events associated with brain metastasis in lung adenocarcinoma.
Deng Z; Cui L; Li P; Ren N; Zhong Z; Tang Z; Wang L; Gong J; Cheng H; Guan Y; Yi X; Xia X; Zhou R; He Z
Cell Death Dis; 2021 Oct; 12(10):935. PubMed ID: 34642306
[TBL] [Abstract] [Full Text] [Related]
4. Targeted inhibition of FGF19/FGFR cascade improves antitumor immunity and response rate in hepatocellular carcinoma.
Tai DWM; Le TBU; Prawira A; Ho RZW; Huynh H
Hepatol Int; 2021 Oct; 15(5):1236-1246. PubMed ID: 34333737
[TBL] [Abstract] [Full Text] [Related]
5. Development of nomogram based on immune-related gene fgfr4 for advanced non-small cell lung cancer patients with sensitivity to immune checkpoint inhibitors.
Wang L; Ren Z; Yu B; Tang J
J Transl Med; 2021 Jan; 19(1):22. PubMed ID: 33407583
[TBL] [Abstract] [Full Text] [Related]
6. Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary.
Bochtler T; Reiling A; Endris V; Hielscher T; Volckmar AL; Neumann O; Kirchner M; Budczies J; Heukamp LC; Leichsenring J; Allgäuer M; Kazdal D; Löffler H; Weichert W; Schirmacher P; Stenzinger A; Krämer A
Int J Cancer; 2020 Jun; 146(11):3053-3064. PubMed ID: 31970771
[TBL] [Abstract] [Full Text] [Related]
7. The fgfr4-388arg Variant Promotes lung cancer Progression by N-Cadherin Induction.
Quintanal-Villalonga Á; Ojeda-Márquez L; Marrugal Á; Yagüe P; Ponce-Aix S; Salinas A; Carnero A; Ferrer I; Molina-Pinelo S; Paz-Ares L
Sci Rep; 2018 Feb; 8(1):2394. PubMed ID: 29402970
[TBL] [Abstract] [Full Text] [Related]
8. Prognostic Role of the fgfr4-388Arg Variant in lung Squamous-Cell Carcinoma Patients With Lymph Node Involvement.
Quintanal-Villalonga Á; Carranza-Carranza A; Meléndez R; Ferrer I; Molina-Pinelo S; Paz-Ares L
Clin Lung Cancer; 2017 Nov; 18(6):667-674.e1. PubMed ID: 28583379
[TBL] [Abstract] [Full Text] [Related]
9. FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib.
Hibi M; Kaneda H; Tanizaki J; Sakai K; Togashi Y; Terashima M; De Velasco MA; Fujita Y; Banno E; Nakamura Y; Takeda M; Ito A; Mitsudomi T; Nakagawa K; Okamoto I; Nishio K
Cancer Sci; 2016 Nov; 107(11):1667-1676. PubMed ID: 27581340
[TBL] [Abstract] [Full Text] [Related]
10. Germline variant fgfr4 p.G388R exposes a membrane-proximal STAT3 binding site.
Ulaganathan VK; Sperl B; Rapp UR; Ullrich A
Nature; 2015 Dec; 528(7583):570-4. PubMed ID: 26675719
[TBL] [Abstract] [Full Text] [Related]
11. The VEGFR2, COX-2 and MMP-2 polymorphisms are associated with clinical outcome of patients with inoperable non-small cell lung cancer.
Butkiewicz D; Krześniak M; Drosik A; Giglok M; Gdowicz-Kłosok A; Kosarewicz A; Rusin M; Masłyk B; Gawkowska-Suwińska M; Suwiński R
Int J Cancer; 2015 Nov; 137(10):2332-42. PubMed ID: 25975224
[TBL] [Abstract] [Full Text] [Related]
12. fgfr4 genetic polymorphisms determine the chemotherapy response of Chinese patients with non-small cell lung cancer.
Fang HM; Tian G; Zhou LJ; Zhou HY; Fang YZ
Acta Pharmacol Sin; 2013 Apr; 34(4):549-54. PubMed ID: 23524567
[TBL] [Abstract] [Full Text] [Related]
13. Meta and pooled analyses of fgfr4 Gly388Arg polymorphism as a cancer prognostic factor.
Frullanti E; Berking C; Harbeck N; Jézéquel P; Haugen A; Mawrin C; Parise O; Sasaki H; Tsuchiya N; Dragani TA
Eur J Cancer Prev; 2011 Jul; 20(4):340-7. PubMed ID: 21412156
[TBL] [Abstract] [Full Text] [Related]
14. Profiling of transcripts and proteins modulated by K-ras oncogene in the lung tissues of K-ras transgenic mice by omics approaches.
Lee S; Kang J; Cho M; Seo E; Choi H; Kim E; Kim J; Kim H; Kang GY; Kim KP; Park YH; Yu DY; Yum YN; Park SN; Yoon DY
Int J Oncol; 2009 Jan; 34(1):161-72. PubMed ID: 19082487
[TBL] [Abstract] [Full Text] [Related]
15. Further observations on the relationship between the fgfr4 Gly388Arg polymorphism and lung cancer prognosis.
Matakidou A; El Galta R; Rudd MF; Webb EL; Bridle H; Eisen T; Houlston RS
Br J Cancer; 2007 Jun; 96(12):1904-7. PubMed ID: 17519899
[TBL] [Abstract] [Full Text] [Related]
16. Functional fgfr4 Gly388Arg polymorphism predicts prognosis in lung adenocarcinoma patients.
Spinola M; Leoni V; Pignatiello C; Conti B; Ravagnani F; Pastorino U; Dragani TA
J Clin Oncol; 2005 Oct; 23(29):7307-11. PubMed ID: 16061909
[TBL] [Abstract] [Full Text] [Related]
